.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
QuintilesIMS
Boehringer Ingelheim
Chinese Patent Office
Argus Health
Queensland Health
Moodys
Dow
Fish and Richardson
Teva

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,399,413

« Back to Dashboard

Which drugs does patent 8,399,413 protect, and when does it expire?


Patent 8,399,413 protects COPAXONE and is included in one NDA. There has been one Paragraph IV challenge on Copaxone.

This patent has fifty-three patent family members in thirty-one countries.

Summary for Patent: 8,399,413

Title:Low frequency glatiramer acetate therapy
Abstract: A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
Inventor(s): Klinger; Ety (Tel Aviv, IL)
Assignee: Yeda Research & Development Co., Ltd. (Rehovot, IL)
Application Number:12/806,684
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Teva Pharms UsaCOPAXONEglatiramer acetateINJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014APRXYesYes► Subscribe► SubscribeMETHOD OF TREATING MS BY ADMINISTERING COPAXONE► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,399,413

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,232,250Low frequency glatiramer acetate therapy► Subscribe
9,402,874Low frequency glatiramer acetate therapy► Subscribe
9,155,776Low frequency glatiramer acetate therapy► Subscribe
8,969,302Low frequency glatiramer acetate therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,399,413

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Eurasian Patent Organization201270292► Subscribe
Eurasian Patent Organization019998► Subscribe
Eurasian Patent Organization201400394► Subscribe
Eurasian Patent Organization201691347► Subscribe
European Patent Office2949335► Subscribe
European Patent Office2405749► Subscribe
European Patent Office2630962► Subscribe
European Patent Office3199172► Subscribe
Spain2424692► Subscribe
Spain2612001► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Chubb
Merck
Chinese Patent Office
Citi
Farmers Insurance
Deloitte
Queensland Health
Healthtrust
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot